Skip to main content
Clinical Trials/CTRI/2012/08/002895
CTRI/2012/08/002895CompletedPhase 4

Assessment of efficacy and safety of desvenlafaxine versus escitalopram in major depressive disorder with symptoms of anxiety:a randomized clinical trial

Department of Pharmacology IPGMER Kolkata0 sites85 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
85

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • subjects of major depressive disorder with symptoms of anxiety with HAM score of seven to eighteen
  • baseline HAMA score more than or equal to twelve
  • Subjects must be willing to give written informed consent

Exclusion Criteria

  • subjects with age less tha eighteen or more than sixty
  • Pregnant and lactating women
  • Baseline HAMD score less than seven or more than eighteen
  • Baseline HAMA score less than 12
  • Subjects with psychotic features
  • Subjects with suicidality catatonic features
  • Subjects on any antidepressant medications in the last two months
  • Subjects with concurrent severe medical disorders like uncontrolled diabetes hypertension ischemic heart disease chronic renal failure cirrhosis any malignancy etc
  • Subjects with history of substance abuse in the last two years
  • Subjects with mixed depression and anxiety disorder or any other episodes of other mood disorder bipolar disorder dysthymia etc
  • Subjects with any other psychiatric disorders
  • Subjects on other concurrent medications known to have drug interact with the study medications like other SSRI SNRI tricyclic antidepressants etc
  • Subjects with past history of anaphylaxis or hypersensitivity to any of the study medications

Investigators

Sponsor
Department of Pharmacology IPGMER Kolkata

Similar Trials